Seeking Alpha

Hospira (HSP), a provider of drug-injection solutions, drops 10.3% premarket after announcing...

Hospira (HSP), a provider of drug-injection solutions, drops 10.3% premarket after announcing preliminary Q3 revenue of $977M (+3% Y/Y) and EPS of $0.66, missing consensus by $30M and $0.29. The shortfall is blamed on quality-improvement initiatives taken in reponse to FDA concerns, along with "device quality and supply-related issues."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs